Longwood launches startup Solu with drug candidates from GSK and $31M to start

Longwood Fund’s Christoph Westphal, the co-founding investor behind the likes of Alnylam, TScan and Tome Biosciences, is out with another new biotech whose pipeline derives from GSK.

Boston-based Solu Therapeutics pulled back the curtains on Tuesday with $31 million in seed capital and drug candidates in-licensed from GSK. The biotech begins with a focus on hematological malignancies and anticipates entering the clinic within two years, co-founder and CEO David Donabedian said in a press release.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Organ aging measured by blood test may help predict age-related diseases

Our organs age at different rates, and a blood test determining how much they’ve each aged could predict the risk of conditions like lung cancer

February 26, 2025

Study offers new insight into how antimicrobial resistance emerges in patients with bacterial infections

A research study led by the University of Oxford provides a transformational new insight into how antimicrobial resistance (AMR) emerges in patients with bacterial infections.

July 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.